Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
hims & hers health, FDA and Trump
Why Hims & Hers Stock Jumped on Massive FDA News
Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.
Hims & Hers Shares Jump as Trump FDA Pick Seen as Major Ally
Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s nomination of Marty Makary to lead the Food and Drug Administration.
Hims & Hers jumps after Trump nominates Dr. Marty Makary for FDA
Shares of Hims & Hers are moving higher after President-elect Donald Trump nominated Dr. Marty Makary, a pancreatic surgeon at Johns
Johns Hopkins Marty Makary, Trump’s choice for FDA, a ‘brilliant surgeon’ with some ‘worrisome’ views
Maryland scholars on Monday alternately described President-elect Donald Trump’s pick to lead the U.S. Food and Drug Administration — Dr. Marty Makary, a Johns Hopkins researcher, surgeon and author — as a “courageous leader” and a “reasonable choice,
Who is Dr. Marty Makary, Trump’s pick to head the FDA?
The nominee, a surgeon at Johns Hopkins, has criticized the use of pesticides on food and the industry turning against “natural fat.”
Trump’s FDA nom has harsh language for chemicals in food
If confirmed as FDA commissioner, Dr. Marty Makary would oversee testing on foods for pollutants like "forever chemicals" and heavy metals.
Money Morning
1d
Three Stocks: Nano Nuclear Energy, Cassava Sciences, and Hims & Hers
Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...
4d
on MSN
Hims & Hers New Growth Category Is a Huge Surprise
Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The ...
6d
Hims & Hers Health: Far From Dead, Even With Amazon's Threat Ahead
Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...
bovnews
2d
Hims & Hers Health Inc (HIMS) Stock: More Strategic Than Meets the Eye
On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $25.33 which represents a slight increase of $1.18 or 4.89% from the prior close of $24.15. The stock opened at ...
1d
Hunterbrook goes long Hims & Hers after short position in June
After going short the stock in June based on Hunterbrook Media’s reporting, Hunterbrook Capital said today it is long Hims & Hers Health.
12d
on MSN
Hims & Hers’ stock tumbles on Amazon’s latest disruptive foray into healthcare
Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...
11d
Hims & Hers: Revolutionizing Telehealth And Captivating Investors - Here's Why You Should Buy
Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...
Wall Street Journal
12d
Hims & Hers Stock Drops After Amazon Says It Will Offer Hair-Loss Treatments
Shares of
Hims
& Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and ...
Fierce Healthcare
11d
Health tech Q3 earnings recap—Hims & Hers, Doximity, Waystar
Waystar upped its 2024 outlook and now expects total revenue to range between $926 million and $934 million, compared to ...
6d
on MSN
Amazon Sets Sights on Both Hims & Hers and Temu. Is This a Golden Opportunity to Buy the Stock?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Presidential transition of Donald Trump
FDA
Food and Drug Administration
Homs
Marty Makary
Feedback